Product Description
SHR-1826 is a novel ADC of a humanized c-MET-directed IgG2 monoclonal antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. (Sourced from: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.106)
Mechanisms of Action: C-MET Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Suzhou Shengdia Biopharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06754930 |
SHR-1826-201-LC | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2027-12-01 |
12% |
2025-04-18 |
Primary Endpoints |
NCT06703177 |
SHR-1826-201 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-01-01 |
12% |
2025-02-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06094556 |
SHR-1826-I-101 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-06-30 |
50% |
2024-02-21 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20233287 |
CTR20233287 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-05-04 |
Patient Enrollment|Treatments |
|
CTR20250604 |
CTR20250604 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|